About
Board of Directors
Steven Muskal, Ph.D.
Chief Executive Officer
Dr. Steven Muskal has over 38 years of experience in the intersection of AI, chemistry, biology, and drug discovery. He has dedicated his career towards improving healthspan, medicine, and general well-being. He is the founder of Sertanty, Inc. and Chief Executive Officer of Eidogen-Sertanty. He holds a Ph.D. in Chemistry from the University of California, Berkeley (1991) - where he was an early pioneer in the use of neural networks to predict features of protein structure - and a B.Sc. in Engineering Chemistry and Computer Science from the Colorado School of Mines (1988).
Before establishing Sertanty, he served as Vice President of Informatics for Libraria, Inc., helping to secure financing while responsible for technology development and operational activity. Before joining Libraria, he served as Unit Director at the Affymax Research Institute and as a member of the Glaxo Wellcome Scientific Computing Board. At Affymax, he directed departments focusing on advanced technologies in parallel synthesis, lead optimization (ADME), and research computing. He held Product Manager, Senior Scientist, and Applications Scientist positions at Molecular Design Limited (MDL Information Systems) while designing, developing, and marketing chemical informatics software.
He has co-authored and contributed to over 50 publications and patents, and has participated in several drug discovery programs in collaboration with academic and industry partners. He is also an advisor to serveral companies that leverage AI and data science. He is driven by the vision of transforming medicine and healthspan through the application of cutting-edge technologies and scientific insight.
Shehan Dissanayake, Ph.D.
Director
Dr. Shehan Dissanayake is the CEO of Tavistock Life Sciences. He oversees all of TLS's operations and portfolio companies, including its investments in Eidogen-Sertanty, CovX, and Kalypsys. Prior to joining TLS, Shehan served as partner in charge of Strategy and Business Planning for Andersen's Global Tax, Human Resource, and Legal operating unit. Shehan received his B.A. in Biology and Chemistry at Skidmore College and a Ph.D. in Cell Physiology from The University of Chicago.
Chris Fuglesang, Ph.D.
Director
Dr. Fuglesang joined Tavistock Life Sciences in 2005. He has responsibilities for portfolio intellectual property, the management of existing portfolio companies, and the identification of prospective public and private investments. Prior to joining Tavistock, Dr. Fuglesang was Vice President at Eidogen, a structural proteomics software company, and a practicing attorney at Perkins Coie LLC in their biotechnology practice group. Dr. Fuglesang received a B.S. in both Chemistry and Physics from the University of California at Los Angeles, a Ph.D. in Theoretical Chemical Physics from the University of California at Los Angeles, and a J.D. from Boston University.
Roy Thiele-Sardiña
Director
Roy Thiele-Sardiña is a co-founder and Managing Partner of HighBar Partners. Over the last 35 years, he has founded, invested in and held senior management positions at numerous prominent companies in the technology industry. Mr. Thiele-Sardiña was a Managing Director with Steelpoint Capital (the private equity subsidiary of Moore Capital Management) and an Executive-In-Residence at the Mayfield Fund. In the mid-90s, Mr. Thiele-Sardiña channeled his investments through HighBAR Ventures, co-founded and held key management positions at Ingrian Networks (acquired by SafeNet), a leading data privacy provider, Tasmania Networks (acquired by Cisco), a cache proxy company and Brocade Communications Systems (Nasdaq: BRCD), a fibre channel switch company. Mr. Thiele-Sardiña was the CEO of Ingrian and Tasmania, and the VP of Sales and Business Development at Brocade. Mr. Thiele-Sardiña worked at Sun Microsystem for 11 years driving its international business from $180M to $1.9B. Mr. Thiele-Sardiña holds a BS in Electrical Engineering and Computer Science from the University of Wisconsin-Madison and an MBA from The Leonard N. Stern School of Business at New York University.
Guillermo Surraco
Director
Guillermo Surraco joined Technofyn Associates LLC as an Associate in 2000. Technofyn Associates LLC is an investment and venture capital firm whose principal owner is Dr. Alejandro Zaffaroni. Previously, Guillermo worked in the areas of marketing and sales for HSQ Technology and Landis & Gyr Systems Inc. He received a BS in Mechanical Engineering from Santa Clara University.
Malcolm Cloyd
Director
Malcolm Cloyd is a founder and managing member of the Athenaeum Fund. He has served as President, Vice President and General Manager of manufacturing and service businesses with domestic and international markets for over 27 years. He has directed business units that were the largest cash contributors for two major corporations and has conducted turnarounds of under-performing businesses for both large corporations and privately held companies. Mr. Cloyd has degrees in management, science and literature.